CGRP Receptor Antagonism in COVID-19: Potential Cardiopulmonary Adverse Effects. Issue 1 (January 2021)

• Record Type: Journal Article
• Authors: Skaria, Tom; Wälchli, Thomas; Vogel, Johannes
• Is Part Of: Trends in molecular medicine. Volume 27:Issue 1(2021)
• Page Start: 7
• Page End: 10
• Publication Date: 2021-01
• Subjects: migraine -- CGRP -- pulmonary hypertension -- right heart failure; Molecular biology -- Periodicals; Pathology, Molecular -- Periodicals; Physiology, Pathological -- Periodicals; 572.8
• DOI: 10.1016/j.molmed.2020.10.005
• Languages: English
• ISSNs: 1471-4914

Abstract

Abstract : Recently, the US FDA has authorized a drug repurposing trial with calcitonin gene-related peptide (CGRP) receptor antagonists to reduce lung inflammation in coronavirus 2019 (COVID-19). However, the well-established cardiopulmonary protective effects of CGRP raise concerns about the safety of antagonizing CGRP in COVID-19. Awareness regarding potential cardiopulmonary adverse effects may enable their early detection and prevent illness from worsening.